Every Form 4 that Veracyte, Inc. (VCYT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VCYT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCYT filings page.
Veracyte, Inc. reported an insider stock sale by its SVP and General Counsel. On 12/16/2025, the officer sold 10,639 shares of common stock at a weighted average price of $43.1277 per share and an additional 100 shares at $43.68 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on August 29, 2025, which automates trades according to preset instructions. Following these sales, the reporting person beneficially owned 67,760 shares of Veracyte common stock, held directly.
Veracyte, Inc. (VCYT) reported an insider stock sale by its Chief Commercial Officer-CLIA. On 11/25/2025, the officer sold 2,808 shares of common stock at $50 per share in a transaction coded "S" (sale). After this trade, the officer beneficially owned 86,291 shares directly. The filing notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025, which is designed to allow insiders to sell shares according to a set schedule.
Veracyte, Inc. (VCYT) reported an insider stock sale by one of its directors. According to the Form 4, the director sold 1,106 shares of Veracyte common stock on 11/25/2025 at a weighted average price of $50.2493 per share, with individual trade prices ranging from $50.005 to $50.66. Following this transaction, the director now beneficially owns 29,362 shares of Veracyte common stock in direct ownership.
The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2024. Such plans allow insiders to sell shares according to a preset schedule or conditions, helping separate trading activity from day-to-day decisions about the company.
Veracyte, Inc. (VCYT) director stock sale reported in a Form 4 filing. A company director filed as a single reporting person and disclosed three open‑market sales of Veracyte common stock on 11/20/2025, all coded as sales. The transactions, made pursuant to a Rule 10b5-1 plan adopted on August 21, 2025, involved 1,491 shares at a weighted average price of $40.9526, 7,049 shares at a weighted average price of $42.4765, and 1,460 shares at a weighted average price of $43.2095.
After these sales, the reporting person beneficially owned 27,199 shares of Veracyte common stock, held directly. The filing notes that each weighted average price represents multiple trades within specified price ranges, and more detailed breakdowns are available to the SEC, the issuer, or a shareholder upon request.
Veracyte (VCYT) insider activity: The company’s VP and Chief Accounting Officer reported open‑market sales of common stock. On 11/07/2025, 5,818 shares were sold at a weighted average price of $40.2078. On 11/10/2025, 5,102 shares were sold at a weighted average price of $42.3321. Following these transactions, beneficial ownership stood at 38,745 shares.
The filing notes that each weighted average reflects multiple trades within disclosed price ranges, with detailed breakdowns available upon request.
Veracyte (VCYT) reported an insider transaction by its SVP, General Counsel. On 11/05/2025, the officer sold 6,466 shares of common stock at $40 per share, coded as an open market sale (S). Following the sale, the reporting person beneficially owned 82,973 shares, held directly. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2024.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.
Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the reporting person sold 9,674 shares of common stock, coded “S”. The weighted average sale price was $40.0239, with individual trades ranging from $40.00 to $40.70.
Following the sale, the insider beneficially owned 13,554 shares, held directly. The transactions were made under a Rule 10b5-1 trading plan adopted on August 20, 2024, which pre‑sets trading instructions.
Veracyte, Inc. (VCYT) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 7,000 shares of common stock at $41 on 11/05/2025, marked with transaction code S. The filing notes the trades were made under a Rule 10b5-1 plan adopted on August 13, 2024.
After the sale, the officer beneficially owns 126,158 shares, held directly.